US Stocks Alert: Illumina surged on September 24 after inclusion in the S&P 500 and sequencing growth

Illumina September 24 Surge Analysis

Keywords: Inclusion in S&P 500, Sequencing Growth

1. On September 21, Illumina was officially included in the S&P 500 Index, replacing Builders FirstSource; index tracking funds may need to allocate to the new constituent stock, resulting in passive allocation demand.

2. In the second quarter of 2026, the company's revenue increased by 9.5% year-on-year to $1.16 billion, with adjusted earnings per share of $1.31, surpassing institutional expectations of $1.23; management raised the full-year adjusted earnings per share guidance to $5.30-$5.40 and increased the guidance for organic revenue growth to above 5%.

3. In the second quarter of 2026, about 78% of clinical sequencing volume was already running on the NovaSeq X platform, and management expects this to rise to 80%–85% by year-end; the adoption of the NovaSeq X platform and demand for clinical consumables are supporting the growth of the sequencing business.

(Disclaimer: This content is generated by AI technology summarizing publicly available information for reference only and does not constitute investment advice.)